To this end, modulation of several underlying pathways by various classes of compounds such as SGLT2 inhibitors, GLP-1 receptor analogs, α-glucosidase inhibitors, and antioxidants are being used to prevent or minimize the gradual progression of heart failure and ongoing treatment challenges. This evidence concerns the gene GLP1R and heart failure.